Among notable releases from emerging markets, Axelspace lowered its operating loss outlook for the current fiscal year, while Ribomic disclosed an interim report on its long-term Phase II dosing study and the continued efficacy of the treatment.
Axelspace's operating loss outlook for the current fiscal year was reportedly revised downward from ¥800 million to ¥2.3 billion.
Ribomic disclosed an interim report on the long-term Phase II dosing study of the achondroplasia treatment umedaptanib pegol, as well as information on the continued efficacy in patients who responded to treatment.
The article contains no specific information on CRAVIA or the other companies, and references to future follow-up reports are limited.